Mepazine hydrochloride Pecazine hydrochloride|cas:2975-36-2|西域试剂

Mepazine hydrochloride Pecazine hydrochloride,98.29%

产品编号：Bellancom-121282A| CAS NO：2975-36-2| 分子式：C₁₉H₂₃ClN₂S| 分子量：346.92

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-121282A	￥1150.00	杭州北京（现货）
Bellancom-121282A	￥1750.00	杭州北京（现货）
Bellancom-121282A	￥2550.00	杭州北京（现货）
Bellancom-121282A	￥4550.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Mepazine hydrochloride Pecazine hydrochloride

产品介绍

Mepazine hydrochloride (Pecazine hydrochloride) 是一种有效的选择性 MALT1 蛋白酶抑制剂。Mepazine hydrochloride 抑制全长 GSTMALT1 和 GSTMALT1 325-760 段的IC₅₀ 分别为 0.83 和 0.42 μM。Mepazine hydrochloride 通过增强细胞凋亡 (apoptosis) 来影响 ABC-DLBCL 细胞的生存能力。

生物活性

Mepazine hydrochloride (Pecazine hydrochloride) is a potent and selective MALT1 protease inhibitor with IC₅₀s of 0.83 and 0.42 μM for GSTMALT1 full length and GSTMALT1 325-760, respectively. Mepazine hydrochloride affects viability of ABC-DLBCL cells by enhancing apoptosis.

体外研究

Mepazine (5-20 μM; 4 days) causes a decrease of cell viability in the activated B cell subtype of diffuse large B cell lymphoma (ABCDLBCL) cells, without significantly affecting GCB-DLBCL cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	ABC-DLBCL cell lines (HBL1, OCI-Ly3, U2932, TMD8, OCI-Ly10) and GCB-DLBCL cell lines (BJAB, Su-DHL-6, Su-DHL-4)
Concentration:	5, 10, and 20 μM
Incubation Time:	4 days
Result:	Caused a decrease of cell viability in the ABC-DLBCL cells HBL1, OCI-Ly3, U2932, and TMD8, without significantly affecting GCB-DLBCL cells.

体内研究
(In Vivo)

Mepazine (16 mg/kg; intraperitoneal administration) interferes with growth and induces apoptosis of ABC-DLBCL cell line OCI-Ly10 in NOD/scid IL-2Rg^null (NSG) mice with a murine DLBCL xenogeneic tumor model. Daily administration of Mepazine strongly impairs the expansion of the ABC-DLBCL cell line OCI-Ly10.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6- to 8-week-old female NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/SzJ (NSG) mice with a murine DLBCL xenogeneic tumor model
Dosage:	400 μg per animal (25 g), corresponding to approximately 16 mg/kg
Administration:	Intraperitoneal administration; started 1 or 12 days after transplantation and given continuously every 24 hr; daily application
Result:	Daily administration strongly impaired the expansion of the ABC-DLBCL cell line OCI-Ly10.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6- to 8-week-old female NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/SzJ (NSG) mice with a murine DLBCL xenogeneic tumor model
Dosage:	400 μg per animal (25 g), corresponding to approximately 16 mg/kg
Administration:	Intraperitoneal administration; started 1 or 12 days after transplantation and given continuously every 24 hr; daily application
Result:	Daily administration strongly impaired the expansion of the ABC-DLBCL cell line OCI-Ly10.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6- to 8-week-old female NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/SzJ (NSG) mice with a murine DLBCL xenogeneic tumor model
Dosage:	400 μg per animal (25 g), corresponding to approximately 16 mg/kg
Administration:	Intraperitoneal administration; started 1 or 12 days after transplantation and given continuously every 24 hr; daily application
Result:	Daily administration strongly impaired the expansion of the ABC-DLBCL cell line OCI-Ly10.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (144.13 mM; Need ultrasonic)

H₂O : 2.22 mg/mL (6.40 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8825 mL	14.4125 mL	28.8251 mL
5 mM	0.5765 mL	2.8825 mL	5.7650 mL
10 mM	0.2883 mL	1.4413 mL	2.8825 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (7.21 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.21 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.21 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.21 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.21 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.21 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
4.

请依序添加每种溶剂： PBS
Solubility: 1.25 mg/mL (3.60 mM); Clear solution; Need ultrasonic and warming and heat to 60°C